Alium: emergence of a new leader in Russian pharma


Alium is Sistema’s pharmaceuticals holding, being created through the merger of Binnopharm, a pharmaceuticals company established by Sistema in 2006, and OBL Pharm. OBL Pharm is an asset Sistema acquired in 2019 as a part of an investment consortium that includes management of OBL Pharm, VTB, Russian Direct Investment Fund (RDIF), Russian-Chinese Investment Funds (RCIF) and a number of leading investments funds from Middle East.

Alium’s total production area exceeds 70,000 sq m and includes four high-tech facilities in Moscow and the Moscow region. These production capacities allow for manufacturing of up to 2 billion tablets, 45 million capsules, 80 million ampoules, 20 million aerosols, 18 million syringes and 14 million infusion solutions per year.

The company's diversified product portfolio comprises about 200 proprietary and generic drugs used to treat nervous and cardiovascular disorders as well as help patients fight pulmonary, respiratory, and gastrointestinal diseases. In addition, the company’s product line includes painkillers and anti-infective drugs. All production processes meet international GMP standards. Product quality is monitored at all stages of production. 

In June 2019, at the St. Petersburg International Economic Forum, Sistema signed an agreement to acquire two pharmaceutical businesses: Sintez and Biocom, which, if merged with Alium, will create a company with a product portfolio of over 500 drugs, and put it in the TOP 3 Russian pharma producers in the commercial segment.

Click here for a video by RBC, Russia’s leading business title (with English subtitles), providing a more detailed overview of the company and an in-depth look into Alium’s production process.